Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial transcription termination factor 4 (MTERF4)
- Target
- MTERF4
- Molecular classification
- Transcription factor, Ribosome biogenesis factor, rRNA binding protein
01
Overview
Mitochondrial transcription termination factor 4 (MTERF4) is a nuclear-encoded, mitochondrial-localized protein belonging to the MTERF family. It is characterized by a repeat all-α-helical domain structure and acts as an rRNA binding protein essential for the proper assembly of the mitochondrial large ribosomal subunit. MTERF4 forms a stoichiometric complex with the rRNA methyltransferase NSUN4, directing NSUN4 to its substrate and conferring sequence specificity for 16S rRNA methylation, a critical modification in ribosome assembly. Mutations or loss of MTERF4 disrupt ribosomal biogenesis and mitochondrial translation, causing severe defects in cellular energy metabolism. MTERF4 is implicated genetically in several human diseases, notably familial restrictive cardiomyopathy and Williams-Beuren syndrome, and is considered an essential factor in mitochondrial function and health.
- Other names
- Transcription termination factor 4, mitochondrialmTERF domain-containing protein 2MTERF4MTERFD2HSPC096MGC61716Mitochondrial transcription termination factor 4
02
Mechanism of action
Not applicable; no targeted drugs or modulators reported.
03
Biological functions
Mitochondrial ribosome assemblyRegulation of mitochondrial RNA methylationrRNA bindingMitochondrial transcription regulation
04
Disease associations
CardiomyopathyWilliams-Beuren syndromeOther mitochondrial diseases
05
Safety considerations
Loss or disruption of MTERF4 function can halt mitochondrial ribosome biogenesis, leading to cessation of mitochondrial translation and cell dysfunction/deathNo safety concerns related to pharmacological targeting are known, as no specific drugs target MTERF4
06
Biomarkers
Mutations or deficiencies of MTERF4 may serve as potential biomarkers in mitochondrial disorder diagnosticsrRNA methylation status (via NSUN4/MTERF4 activity) could serve as a research biomarker for mitochondrial function but is not established in clinical use
Beyond the preview
Go deeper on Mitochondrial transcription termination factor 4 (MTERF4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitochondrial transcription termination factor 4 (MTERF4).